{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-308488","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2026-07-20T13:18:31+00:00","discovered_at":"2026-07-20T13:20:00.332596+00:00","generated_at":"2026-07-20T13:20:05.443049+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Tempus to acquire Personalis for $16.25/share, $1.5B enterprise value","bullets":["Consideration of $16.25 per share, 6% premium to last close, 28% premium to 30-day VWAP.","Total enterprise value of $1.5B net of Tempus' existing ownership; 100% stock with cash option up to 50%.","Closing expected late 2026 or early 2027; subject to Personalis shareholder and regulatory approvals.","Personalis reports preliminary Q2 revenue of $22.4M and 10,384 clinical tests, up 33% QoQ.","Acquisition combines Personalis' MRD technology with Tempus' AI platform; MRD market opportunity $20B."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-308488","json":"https://secwatch.observer/filing/0001193125-26-308488.json","markdown":"https://secwatch.observer/filing/0001193125-26-308488.md","text":"https://secwatch.observer/filing/0001193125-26-308488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000119312526308488/0001193125-26-308488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000119312526308488/d68794d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-20T13:20:05.443049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}